keyword
MENU ▼
Read by QxMD icon Read
search

in-vivo dosimetry

keyword
https://www.readbyqxmd.com/read/28821924/-89-zr-labeled-nivolumab-for-imaging-of-t-cell-infiltration-in-a-humanized-murine-model-of-lung-cancer
#1
Christopher G England, Dawei Jiang, Emily B Ehlerding, Brian T Rekoske, Paul A Ellison, Reinier Hernandez, Todd E Barnhart, Douglas G McNeel, Peng Huang, Weibo Cai
PURPOSE: Nivolumab is a human monoclonal antibody specific for programmed cell death-1 (PD-1), a negative regulator of T-cell activation and response. Acting as an immune checkpoint inhibitor, nivolumab binds to PD-1 expressed on the surface of many immune cells and prevents ligation by its natural ligands. Nivolumab is only effective in a subset of patients, and there is limited evidence supporting its use for diagnostic, monitoring, or stratification purposes. METHODS: (89)Zr-Df-nivolumab was synthesized to map the biodistribution of PD-1-expressing tumor infiltrating T-cells in vivo using a humanized murine model of lung cancer...
August 19, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28816053/in-vitro-exposure-systems-and-dosimetry-assessment-tools-for-inhaled-tobacco-products-workshop-proceedings-conclusions-and-paths-forward-for-in-vitro-model-use
#2
Holger Behrsing, Erin Hill, Hans Raabe, Raymond Tice, Suzanne Fitzpatrick, Robert Devlin, Kent Pinkerton, Günter Oberdörster, Chris Wright, Roman Wieczorek, Michaela Aufderheide, Sandro Steiner, Tobias Krebs, Bahman Asgharian, Richard Corley, Michael Oldham, Jason Adamson, Xiang Li, Irfan Rahman, Sonia Grego, Pei-Hsuan Chu, Shaun McCullough, Rodger Curren
In 2009, the passing of the Family Smoking Prevention and Tobacco Control Act facilitated the establishment of the FDA Center for Tobacco Products (CTP), and gave it regulatory authority over the marketing, manufacture and distribution of tobacco products, including those termed 'modified risk'. On 4-6 April 2016, the Institute for In Vitro Sciences, Inc. (IIVS) convened a workshop conference entitled, In Vitro Exposure Systems and Dosimetry Assessment Tools for Inhaled Tobacco Products, to bring together stakeholders representing regulatory agencies, academia and industry to address the research priorities articulated by the FDA CTP...
July 2017: Alternatives to Laboratory Animals: ATLA
https://www.readbyqxmd.com/read/28796750/in-vivo-electron-paramagnetic-resonance-tooth-dosimetry-dependence-of-radiation-induced-signal-amplitude-on-the-enamel-thickness-and-surface-area-of-ex-vivo-human-teeth
#3
Michitaka Umakoshi, Ichiro Yamaguchi, Hiroshi Hirata, Naoki Kunugita, Benjamin B Williams, Harold M Swartz, Minoru Miyake
In vivo L-band electron paramagnetic resonance tooth dosimetry is a newly developed and very promising method for retrospective biodosimetry in individuals who may have been exposed to significant levels of ionizing radiation. The present study aimed to determine the relationships among enamel thickness, enamel area, and measured electron paramagnetic resonance signal amplitude with a view to improve the quantitative accuracy of the dosimetry technique. Ten isolated incisors were irradiated using well-characterized doses, and their radiation-induced electron paramagnetic resonance signals were measured...
August 7, 2017: Health Physics
https://www.readbyqxmd.com/read/28760446/in-vitro-to-in-vivo-extrapolation-of-effective-dosimetry-in-developmental-toxicity-testing-application-of-a-generic-pbk-modelling-approach
#4
Styliani Fragki, Aldert H Piersma, Emiel Rorije, Marco J Zeilmaker
Incorporation of kinetics to quantitative in vitro to in vivo extrapolations (QIVIVE) is a key step for the realization of a non-animal testing paradigm, in the sphere of regulatory toxicology. The use of Physiologically-Based Kinetic (PBK) modelling for determining systemic doses of chemicals at the target site is accepted to be an indispensable element for such purposes. Nonetheless, PBK models are usually designed for a single or a group of compounds and are considered demanding, with respect to experimental data needed for model parameterization...
July 28, 2017: Toxicology and Applied Pharmacology
https://www.readbyqxmd.com/read/28751451/131i-labeled-anti-her2-camelid-sdab-as-a-theranostic-tool-in-cancer-treatment
#5
Matthias D'Huyvetter, Jens De Vos, Catarina Xavier, Marek Pruszynski, Yann G J Sterckx, Sam Massa, Geert Raes, Vicky Caveliers, Michael Zalutsky, Tony Lahoutte, Nick Devoogdt
<p>Camelid single-domain antibody-fragments (sdAbs) have beneficial pharmacokinetic properties, and those targeted to HER2 can be used for imaging of HER2-overexpressing cancer. Labeled with a therapeutic radionuclide, they may be used for HER2-targeted therapy. Here we describe the generation of a (131)I-labeled sdAb as a theranostic drug to treat HER2-overexpressing cancer.</p> <br />Experimental Design: <p>Anti-HER2 sdAb 2Rs15d was labeled with (131)I using [(131)I]SGMIB and evaluated in vitro Biodistribution was evaluated in two HER2(+) murine xenograft models by micro-SPECT/CT imaging and at necropsy, and under challenge with trastuzumab and pertuzumab...
July 27, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28747518/targeted-molecular-radiotherapy-of-pediatric-solid-tumors-using-a-radioiodinated-alkyl-phospholipid-ether-analog
#6
Dana C Baiu, Ian R Marsh, Alexander E Boruch, Ankita Shahi, Saswati Bhattacharya, Justin J Jeffery, Qianqian Zhao, Lance Hall, Jamey P Weichert, Bryan Bednarz, Mario Otto
External beam radiotherapy plays a critical role in the treatment of most pediatric solid tumors. Particularly in children, achieving an optimal therapeutic index to avoid damage to normal tissue is extremely important. Consequently, in metastatic disease, the utility of external beam radiotherapy is very limited. Molecular radiotherapy with tumor-targeted radionuclides may overcome some of these challenges, but to date no single cancer selective agent exists, capable of treating various pediatric malignancies independent of their histopathological origin...
July 26, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28744319/-177-lu-pentixather-comprehensive-preclinical-characterization-of-a-first-cxcr4-directed-endoradiotherapeutic-agent
#7
Margret Schottelius, Theresa Osl, Andreas Poschenrieder, Frauke Hoffmann, Seval Beykan, Heribert Hänscheid, Andreas Schirbel, Andreas K Buck, Saskia Kropf, Markus Schwaiger, Ulrich Keller, Michael Lassmann, Hans-Jürgen Wester
Purpose: Based on the clinical relevance of the chemokine receptor 4 (CXCR4) as a molecular target in cancer and on the success of [(68)Ga]pentixafor as an imaging probe for high-contrast visualization of CXCR4-expression, the spectrum of clinical CXCR4-targeting was expanded towards peptide receptor radionuclide therapy (PRRT) by the development of [(177)Lu]pentixather. Experimental design: CXCR4 affinity, binding specificity, hCXCR4 selectivity and internalization efficiency of [(177)Lu]pentixather were evaluated using different human and murine cancer cell lines...
2017: Theranostics
https://www.readbyqxmd.com/read/28721684/pharmacokinetics-microscale-distribution-and-dosimetry-of-alpha-emitter-labeled-anti-pd-l1-antibodies-in-an-immune-competent-transgenic-breast-cancer-model
#8
Jessie R Nedrow, Anders Josefsson, Sunju Park, Tom Bäck, Robert F Hobbs, Cory Brayton, Frank Bruchertseifer, Alfred Morgenstern, George Sgouros
BACKGROUND: Studies combining immune checkpoint inhibitors with external beam radiation have shown a therapeutic advantage over each modality alone. The purpose of these works is to evaluate the potential of targeted delivery of high LET radiation to the tumor microenvironment via an immune checkpoint inhibitor. METHODS: The impact of protein concentration on the distribution of (111)In-DTPA-anti-PD-L1-BC, an (111)In-antibody conjugate targeted to PD-L1, was evaluated in an immunocompetent mouse model of breast cancer...
December 2017: EJNMMI Research
https://www.readbyqxmd.com/read/28714454/a-back-projection-algorithm-in-the-presence-of-an-extra-attenuating-medium-towards-epid-dosimetry-for-the-mr-linac
#9
I Torres-Xirau, I Olaciregui-Ruiz, R A Rozendaal, P González, B J Mijnheer, J-J Sonke, U A van der Heide, A Mans
In external beam radiotherapy, electronic portal imaging devices (EPIDs) are frequently used for pre-treatment and for in vivo dose verification. Currently, various MR-guided radiotherapy systems are being developed and clinically implemented. Independent dosimetric verification is highly desirable. For this purpose we adapted our EPID-based dose verification system for use with the MR-Linac combination developed by Elekta in cooperation with UMC Utrecht and Philips. In this study we extended our back-projection method to cope with the presence of an extra attenuating medium between the patient and the EPID...
July 17, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28712278/in-vivo-dosimetry-and-acute-toxicity-in-breast-cancer-patients-undergoing-intraoperative-radiotherapy-as-boost
#10
Jason Joon Bock Lee, Jinhyun Choi, Sung Gwe Ahn, Joon Jeong, Ik Jae Lee, Kwangwoo Park, Kangpyo Kim, Jun Won Kim
PURPOSE: To report the results of a correlation analysis of skin dose assessed by in vivo dosimetry and the incidence of acute toxicity. This is a phase 2 trial evaluating the feasibility of intraoperative radiotherapy (IORT) as a boost for breast cancer patients. MATERIALS AND METHODS: Eligible patients were treated with IORT of 20 Gy followed by whole breast irradiation (WBI) of 46 Gy. A total of 55 patients with a minimum follow-up of 1 month after WBI were evaluated...
June 2017: Radiation Oncology Journal
https://www.readbyqxmd.com/read/28696500/development-of-a-silicon-diode-detector-for-skin-dosimetry-in-radiotherapy
#11
Nikolina Vicoroski, Anthony Espinoza, Mitchell Duncan, Bradley Michael Oborn, Martin Carolan, Peter Metcalfe, David Menichelli, Vladimir L Perevertaylo, Michael L F Lerch, Anatoly B Rosenfeld, Marco Petasecca
PURPOSE: The aim of in-vivo skin dosimetry is to measure the absorbed dose to the skin during radiotherapy, when treatment planning calculations cannot be relied on. It is of particularly importance in hypo-fractionated stereotactic modalities, where excessive dose can lead to severe skin toxicity. Currently commercial diodes for such applications are with water equivalent depths ranging from 0.5 to 0.8 mm. In this study, we investigate a new detector for skin dosimetry based on a silicon epitaxial diode, referred to as the skin diode...
July 11, 2017: Medical Physics
https://www.readbyqxmd.com/read/28663056/from-in-vitro-to-in-vivo-integration-of-the-virtual-cell-based-assay-with-physiologically-based-kinetic-modelling
#12
Alicia Paini, Jose Vicente Sala Benito, Jos Bessems, Andrew P Worth
Physiologically based kinetic (PBK) models and the virtual cell based assay can be linked to form so called physiologically based dynamic (PBD) models. This study illustrates the development and application of a PBK model for prediction of estragole-induced DNA adduct formation and hepatotoxicity in humans. To address the hepatotoxicity, HepaRG cells were used as a surrogate for liver cells, with cell viability being used as the in vitro toxicological endpoint. Information on DNA adduct formation was taken from the literature...
June 27, 2017: Toxicology in Vitro: An International Journal Published in Association with BIBRA
https://www.readbyqxmd.com/read/28654303/imaging-and-dosimetry-for-radium-223-the-potential-for-personalized-treatment
#13
Glenn D Flux
Radium-223 ((223)Ra) offers a new option for the treatment of bone metastases from prostate cancer. As cancer treatment progresses towards personalization, the potential for an individualized approach is exemplified in treatments with radiotherapeutics due to the unique ability to image in vivo the uptake and retention of the therapeutic agent. This is unmatched in any other field of medicine. Currently, (223)Ra is administered according to standard fixed administrations, modified according to patient weight...
June 27, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28643752/dosimetric-characterization-of-optically-stimulated-luminescence-dosimeter-with-therapeutic-photon-beams-for-use-in-clinical-radiotherapy-measurements
#14
Retna Ponmalar, Ravikumar Manickam, K M Ganesh, Sathiyan Saminathan, Arun Raman, Henry Finlay Godson
AIM: The modern radiotherapy techniques impose new challenges for dosimetry systems with high precision and accuracy in in vivo and in phantom dosimetric measurements. The knowledge of the basic characterization of a dosimetric system before patient dose verification is crucial. This incites the investigation of the potential use of nanoDot optically stimulated luminescence dosimeter (OSLD) for application in radiotherapy with therapeutic photon beams. MATERIALS AND METHODS: Measurements were carried out with nanoDot OSLDs to evaluate the dosimetric characteristics such as dose linearity, dependency on field size, dose rate, energy and source-to-surface distance (SSD), reproducibility, fading effect, reader stability, and signal depletion per read out with cobalt-60 (60 Co) beam, 6 and 18 MV therapeutic photon beams...
April 2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28641969/determining-3d-kinematics-of-the-hip-using-video-fluoroscopy-guidelines-for-balancing-radiation-dose-and-registration-accuracy
#15
Fabio D'Isidoro, Patrik Eschle, Thomas Zumbrunn, Christian Sommer, Stephan Scheidegger, Stephen J Ferguson
BACKGROUND: Video fluoroscopy is a technique currently used to retrieve the in vivo three-dimensional kinematics of human joints during activities of daily living. Minimization of the radiation dose absorbed by the subject during the measurement is a priority and has not been thoroughly addressed so far. This issue is critical for the motion analysis of the hip joint, because of the proximity of the gonads. The aims of this study were to determine the x-ray voltage and the irradiation angle that minimize the effective dose and to achieve the best compromise between delivered dose and accuracy in motion retrieval...
May 25, 2017: Journal of Arthroplasty
https://www.readbyqxmd.com/read/28613198/lu-177-psma-617-prostate-specific-membrane-antigen-inhibitor-therapy-in-patients-with-castration-resistant-prostate-cancer-stability-bio-distribution-and-dosimetry
#16
Levent Kabasakal, Türkay Toklu, Nami Yeyin, Emre Demirci, Mohammad Abuqbeitah, Meltem Ocak, Aslan Aygün, Emre Karayel, Hüseyin Pehlivanoğlu, Nalan Alan Selçuk
OBJECTIVE: The aim of the study was to estimate the radiation-absorbed doses and to study the in vivo and in vitro stability as well as pharmacokinetic characteristics of lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA)-617. METHODS: For this purpose, 7 patients who underwent Lu-177-PSMA therapy were included into the study. The injected Lu-177-PSMA-617 activity ranged from 3.6 to 7.4 GBq with a mean of 5.2±1.8 GBq. The stability of radiotracer in saline was calculated up to 48 h...
June 1, 2017: Molecular Imaging and Radionuclide Therapy
https://www.readbyqxmd.com/read/28596540/preparation-and-in-vivo-characterization-of-51-mncl2-as-pet-tracer-of-ca-2-channel-mediated-transport
#17
Stephen A Graves, Reinier Hernandez, Hector F Valdovinos, Paul A Ellison, Jonathan W Engle, Todd E Barnhart, Weibo Cai, Robert J Nickles
Manganese has long been employed as a T1-shortening agent in magnetic resonance imaging (MRI) applications, but these techniques are limited by the biotoxicity of bulk-manganese. Positron emission tomography (PET) offers superior contrast sensitivity compared with MRI, and recent preclinical PET studies employing (52g)Mn (t1/2: 5.6 d, β(+): 29%) show promise for a variety of applications including cell tracking, neural tract tracing, immunoPET, and functional β-cell mass quantification. The half-life and confounding gamma emissions of (52g)Mn are prohibitive to clinical translation, but the short-lived (51)Mn (t1/2: 46 min, β(+): 97%) represents a viable alternative...
June 8, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28585491/a-simple-method-for-2-d-in-vivo-dosimetry-by-portal-imaging
#18
Stefano Peca, Derek Wilson Brown, Wendy Lani Smith
PURPOSE: To improve patient safety and treatment quality, verification of dose delivery in radiotherapy is desirable. We present a simple, easy-to-implement, open-source method for in vivo planar dosimetry of conformal radiotherapy by electronic portal imaging device (EPID). METHODS: Correlation ratios, which relate dose in the mid-depth of slab phantoms to transit EPID signal, were determined for multiple phantom thicknesses and field sizes. Off-axis dose is corrected for by means of model-based convolution...
January 1, 2017: Technology in Cancer Research & Treatment
https://www.readbyqxmd.com/read/28585490/in-vivo-portal-imaging-dosimetry-identifies-delivery-errors-in-rectal-cancer-radiotherapy-on-the-belly-board-device
#19
Stefano Peca, Richie Siddhartha Sinha, Derek Wilson Brown, Wendy Lani Smith
PURPOSE: We recently developed a novel, open-source in vivo dosimetry that uses the electronic portal imaging device to detect dose delivery discrepancies. We applied our method on patients with rectal cancer treated on a belly board device. METHODS: In vivo dosimetry was performed on 10 patients with rectal cancer treated prone on the belly board with a 4-field box arrangement. Portal images were acquired approximately once per week from each treatment beam. Our dosimetry method used these images along with the planning CT to reconstruct patient planar dose at isocenter depth...
January 1, 2017: Technology in Cancer Research & Treatment
https://www.readbyqxmd.com/read/28585232/in-vitro-in-silico-based-analysis-of-the-dose-dependent-in-vivo-oestrogenicity-of-the-soy-phytoestrogen-genistein-in-humans
#20
Rungnapa Boonpawa, Albertus Spenkelink, Ans Punt, Ivonne M C M Rietjens
BACKGROUND AND PURPOSE: The in vivo oestrogenicity of genistein and its glycoside genistin is still under debate. The present study aimed to develop a physiologically based kinetic (PBK) model that provides insight in dose-dependent plasma concentrations of genistein aglycone and its metabolites and enables prediction of in vivo oestrogenic effective dose levels of genistein and genistin in humans. EXPERIMENTAL APPROACH: A PBK model for genistein and genistin in humans was developed based on in vitro metabolic parameters...
August 2017: British Journal of Pharmacology
keyword
keyword
100206
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"